
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYTIGA | Johnson & Johnson | N-202379 RX | 2011-04-28 | 2 products, RLD |
| YONSA | Sun Pharmaceutical Industries | N-210308 RX | 2018-05-22 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AKEEGA | Johnson & Johnson | N-216793 RX | 2023-08-11 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| abiraterone | ANDA | 2025-08-19 |
| abiraterone acetate | ANDA | 2025-09-16 |
| abirtega | ANDA | 2025-02-28 |
| akeega | New Drug Application | 2024-08-19 |
| yonsa | Export only | 2025-09-22 |
| zytiga | New Drug Application | 2025-03-28 |
Expiration | Code | ||
|---|---|---|---|
ABIRATERONE ACETATE / NIRAPARIB TOSYLATE, AKEEGA, JANSSEN BIOTECH | |||
| 2026-08-11 | NP | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Abiraterone Acetate / Niraparib Tosylate, Akeega, Janssen Biotech | |||
| 11091459 | 2038-03-27 | DS, DP | |
| 11673877 | 2038-03-27 | DS, DP | |
| 11207311 | 2037-07-28 | U-2830 | |
| 8859562 | 2031-08-04 | U-2830 | |
| 8071623 | 2031-03-27 | DS, DP | |
| 8436185 | 2029-04-24 | DS, DP | |
| 8071579 | 2027-08-12 | U-2830 | |
| 8143241 | 2027-08-12 | U-2830 | |
| Abiraterone Acetate, Yonsa, Sun Pharm | |||
| 10292990 | 2034-05-20 | U-2535 | |
| 9889144 | 2034-03-17 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 13 | 26 | 9 | — | 8 | 53 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 3 | 5 | 3 | — | 1 | 11 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Postmenopause | D017698 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | 1 | — | — | — | — | 1 |
| Adrenogenital syndrome | D047808 | — | E25.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | — | — | 1 | 1 |
| Male genital diseases | D005832 | EFO_0009555 | N50.9 | — | — | — | — | 1 | 1 |
| Male genital neoplasms | D005834 | — | — | — | — | — | — | 1 | 1 |
| Genital diseases | D000091662 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Abiraterone |
| INN | abiraterone |
| Description | Abiraterone acetate is a sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. It has a role as a prodrug, an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a sterol ester and a member of pyridines. It is functionally related to an abiraterone. |
| Classification | Small molecule |
| Drug class | antiandrogens |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1 |
| PDB | — |
| CAS-ID | 154229-19-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL254328 |
| ChEBI ID | 68642 |
| PubChem CID | 9821849 |
| DrugBank | DBSALT001173 |
| UNII ID | G819A456D0 (ChemIDplus, GSRS) |



